Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Patients with neuroendocrine tumors have few treatment options after progression to first-line somatostatin analogues.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Carmona Bayonas A
Authors: Carmona-Bayonas A, Mitjavila Casanovas M, Belló P, Percovich J, Prieto A,
Keywords: PRRT, 177Lu-DOTATATE, radionuclide,
Introduction: Somatostatin analogues (SSAs) are the cornerstone of systemic therapy of advanced NETs. The efficacy controlling hormone release and tumor growth together with the favorable toxicity profile have positioned SSAs as upfront therapy. Despite of second-line therapies including targeted agents, chemotherapy and radiolabeled peptides have demonstrated activity controlling tumor growth, the less favorable toxicity profiles become a usual discussion with patients (pts) to preserve the quality of life (QoL). Additionally, from concordant flow of evidences clinical benefits could be obtained with higher SSAs circulating levels but remain unreachable with current products. APOC is a new controlled release ready-to-use convenient therapeutic, designed to cover specifically these clinical unmet needs.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Capdevila J
Authors: Capdevila J, Hernando J, Casanovas O, Lachamp L, Cabello F,
Keywords: Somatostatin analogues, New release mechanism, High doses,
Introduction: Somatostatin analogues (SSA) such as Octreotide and Lanreotide have demonstrated a significant benefit in Neuroendocrine Tumors, particularly in the well/moderately differentiated types. Nevertheless, there are still several aspects of SSA treatments that remain unsolved, such as drug exposition in patients and schedule optimization.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Casanovas O
Authors: Martínez-López A, Pinto J, Lachamp L, Cabello F, Cherif-Cheikh R,
Keywords: Somatostatin Analogs, Octreotide, pNETs, dose scheduling.,
Introduction: Somatostatin analogues (SSAs) are considered the gold standard for systemic therapy of advanced neuroendocrine tumors (NETs). Octreotide is one of the SSAs most widely used in long-term therapies of NETs. There is increasing evidence that clinical benefits could be obtained with higher SSAs circulating levels but remain unreachable with current products without impacting significantly the quality of life of the patients. APOC is a new injectable controlled release technology containing Octreotide invented and developed by Ascil-Biopharm and designed to cover specifically these clinical unmet needs. It is presented as ready-to-use and can easily be manufactured at selected doses and durations in prefilled syringe.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Antonijoan Arbós R, Lachamp L, Cabello F, Molina P, Coimbra J,
Keywords: Apoc, somatostatin, analogues, controlled release, octreotide, octreotide acetate, phase 1, studies, clinical trial, study, neuroendocrine, tumor, slow, release, formulation, therapeutics, injection, drug effect, clinical, trial, im, sc,
#1537 Antitumor Efficacy of Temozolomide in Patients with Metastatic Pulmonary Carcinoids
Introduction: Temodal (TMZ) is an oral alternative to dacarbazine.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author:
Authors: Bello Roufai D, Planchard D, Walter T, Berdelou A, Guigay J,
Keywords: pulmonary carcinoids, temozolomide, safety,